Search research articles
Contact Us
Filters
Showing results (281-290 of 487) with videos related to
Page
of 49
Sort By:
Critical Reviews in Oncology/Hematology
|
July 2, 2024
From theory to practice: Implementing next-generation sequencing and public health genomics in healthcare systems
Denis Horgan, Filippo Pesapane, Marc Van der Buckle, et al.
Oncology Research and Treatment
|
September 13, 2021
A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events
Patrick Schöffski, Nicole Concin, Cristina Suarez, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 13, 2022
Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study
Federico Longo-Muñoz, Daniel Castellano, Jerome Alexandre, et al.
JCO Precision Oncology
|
December 5, 2025
Clinical Presentation of <i>MTAP</i> Deletions in Real-World Settings: Lessons for the Clinical Development of Novel Targeted Therapies
Jordan T Best, Xiaotong Fu, Sripraharsha S Jampana Raju, et al.
The Oncologist
|
March 17, 2021
Overview of Ocular Side Effects of Selinexor
Nagham Al-Zubidi, Dan S Gombos, David S Hong, et al.
Cancer Medicine
|
February 24, 2024
Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors
Niamh Coleman, Bettzy Stephen, Siqing Fu, et al.
Journal for Immunotherapy of Cancer
|
December 20, 2017
Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
Roman Groisberg, David S Hong, Amini Behrang, et al.
Anticancer Research
|
June 26, 2024
Proceedings of the Think Tank for Osteosarcoma Medical Advisory Board
Sant P Chawla, Brian VAN Tine, Noah Federman, et al.
Surgery
|
October 26, 2019
Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in sporadic medullary thyroid carcinoma
Jessica E Maxwell, Maria K Gule-Monroe, Vivek Subbiah, et al.
Head & Neck
|
November 10, 2020
Neoadjuvant selpercatinib for advanced medullary thyroid cancer
Yelda Jozaghi, Mark Zafereo, Michelle D Williams, et al.
Page
of 49
Search research articles
Search
Showing results (281-290 of 487) with videos related to
Sort By:
Page
of 49
Critical Reviews in Oncology/Hematology
|
July 2, 2024
From theory to practice: Implementing next-generation sequencing and public health genomics in healthcare systems
Denis Horgan, Filippo Pesapane, Marc Van der Buckle, et al.
Oncology Research and Treatment
|
September 13, 2021
A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events
Patrick Schöffski, Nicole Concin, Cristina Suarez, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 13, 2022
Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study
Federico Longo-Muñoz, Daniel Castellano, Jerome Alexandre, et al.
JCO Precision Oncology
|
December 5, 2025
Clinical Presentation of <i>MTAP</i> Deletions in Real-World Settings: Lessons for the Clinical Development of Novel Targeted Therapies
Jordan T Best, Xiaotong Fu, Sripraharsha S Jampana Raju, et al.
The Oncologist
|
March 17, 2021
Overview of Ocular Side Effects of Selinexor
Nagham Al-Zubidi, Dan S Gombos, David S Hong, et al.
Cancer Medicine
|
February 24, 2024
Phase I study of sapanisertib (CB-228/TAK-228/MLN0128) in combination with ziv-aflibercept in patients with advanced solid tumors
Niamh Coleman, Bettzy Stephen, Siqing Fu, et al.
Journal for Immunotherapy of Cancer
|
December 20, 2017
Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
Roman Groisberg, David S Hong, Amini Behrang, et al.
Anticancer Research
|
June 26, 2024
Proceedings of the Think Tank for Osteosarcoma Medical Advisory Board
Sant P Chawla, Brian VAN Tine, Noah Federman, et al.
Surgery
|
October 26, 2019
Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in sporadic medullary thyroid carcinoma
Jessica E Maxwell, Maria K Gule-Monroe, Vivek Subbiah, et al.
Head & Neck
|
November 10, 2020
Neoadjuvant selpercatinib for advanced medullary thyroid cancer
Yelda Jozaghi, Mark Zafereo, Michelle D Williams, et al.
Page
of 49